[
  {
    "ts": null,
    "headline": "Pharma Stocks Are Close to Breaking Out. Earnings Could Set Them Free.",
    "summary": "Pharmaceutical stocks just broke out to new highs—and earnings could push them even higher.  The  exchange-traded fund is up 32% in the past six months to almost $57.  Also helping the rally is that healthcare companies are investing in artificial intelligence to help them identify revenue opportunities with lower costs, potentially lifting profit margins.",
    "url": "https://finnhub.io/api/news?id=d680fcc926368f93c29c79205fee63d7f68d21e64787987f131581084144d6b6",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1769622420,
      "headline": "Pharma Stocks Are Close to Breaking Out. Earnings Could Set Them Free.",
      "id": 138287497,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "MRK",
      "source": "Yahoo",
      "summary": "Pharmaceutical stocks just broke out to new highs—and earnings could push them even higher.  The  exchange-traded fund is up 32% in the past six months to almost $57.  Also helping the rally is that healthcare companies are investing in artificial intelligence to help them identify revenue opportunities with lower costs, potentially lifting profit margins.",
      "url": "https://finnhub.io/api/news?id=d680fcc926368f93c29c79205fee63d7f68d21e64787987f131581084144d6b6"
    }
  },
  {
    "ts": null,
    "headline": "Merck's Non-Oncology Drugs Q4 Performance: What to Expect",
    "summary": "MRK's focus shifts beyond Keytruda in Q4 as investors watch new products Capvaxive and Winrevair, as well as Animal Health business sales performance.",
    "url": "https://finnhub.io/api/news?id=6dd035107dd917d10cce0222e5b883f3a05e0749d794127b10a8ed0bf477692c",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1769613300,
      "headline": "Merck's Non-Oncology Drugs Q4 Performance: What to Expect",
      "id": 138285049,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "MRK",
      "source": "Yahoo",
      "summary": "MRK's focus shifts beyond Keytruda in Q4 as investors watch new products Capvaxive and Winrevair, as well as Animal Health business sales performance.",
      "url": "https://finnhub.io/api/news?id=6dd035107dd917d10cce0222e5b883f3a05e0749d794127b10a8ed0bf477692c"
    }
  },
  {
    "ts": null,
    "headline": "AbbVie (ABBV) Reports Next Week: Wall Street Expects Earnings Growth",
    "summary": "AbbVie (ABBV) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.",
    "url": "https://finnhub.io/api/news?id=e348e36191adff74703e15dd1911bc697362f0832b9d5de5b8e48d92d83b9f1b",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1769612411,
      "headline": "AbbVie (ABBV) Reports Next Week: Wall Street Expects Earnings Growth",
      "id": 138285063,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "MRK",
      "source": "Yahoo",
      "summary": "AbbVie (ABBV) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.",
      "url": "https://finnhub.io/api/news?id=e348e36191adff74703e15dd1911bc697362f0832b9d5de5b8e48d92d83b9f1b"
    }
  },
  {
    "ts": null,
    "headline": "North America Gas Chromatography Market Forecast Report 2025-2033 Featuring Agilent, Bio-Rad, Chromatotec, Merck, PerkinElmer, Phenomenex, Restek, Shimadzu, Thermo Fisher Scientific, Waters",
    "summary": "The North America Gas Chromatography Market is projected to grow from US$ 1.69 billion in 2025 to US$ 2.64 billion by 2033, at a CAGR of 5.75%. This growth is fueled by stringent environmental regulations, the expansion of pharmaceutical and biotech R&D, and rising demand for analytical testing in petrochemicals and environmental sectors. Key drivers include technological innovations, automation, and integrated GC solutions, alongside a heightened focus on sustainability. However, challenges lik",
    "url": "https://finnhub.io/api/news?id=3cd25c589aa3d2c35cc05e06fe822da8136a1cba30f957d794b16dc55b0a94f3",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1769612280,
      "headline": "North America Gas Chromatography Market Forecast Report 2025-2033 Featuring Agilent, Bio-Rad, Chromatotec, Merck, PerkinElmer, Phenomenex, Restek, Shimadzu, Thermo Fisher Scientific, Waters",
      "id": 138281506,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "MRK",
      "source": "Yahoo",
      "summary": "The North America Gas Chromatography Market is projected to grow from US$ 1.69 billion in 2025 to US$ 2.64 billion by 2033, at a CAGR of 5.75%. This growth is fueled by stringent environmental regulations, the expansion of pharmaceutical and biotech R&D, and rising demand for analytical testing in petrochemicals and environmental sectors. Key drivers include technological innovations, automation, and integrated GC solutions, alongside a heightened focus on sustainability. However, challenges lik",
      "url": "https://finnhub.io/api/news?id=3cd25c589aa3d2c35cc05e06fe822da8136a1cba30f957d794b16dc55b0a94f3"
    }
  },
  {
    "ts": null,
    "headline": "Brokers Suggest Investing in Merck (MRK): Read This Before Placing a Bet",
    "summary": "Based on the average brokerage recommendation (ABR), Merck (MRK) should be added to one's portfolio. Wall Street analysts' overly optimistic recommendations cast doubt on the effectiveness of this highly sought-after metric. So, is the stock worth buying?",
    "url": "https://finnhub.io/api/news?id=523c1e805c44395f4d292b77d7bba21fef8e9317fc950d749126b5591f581a93",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1769610604,
      "headline": "Brokers Suggest Investing in Merck (MRK): Read This Before Placing a Bet",
      "id": 138281507,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "MRK",
      "source": "Yahoo",
      "summary": "Based on the average brokerage recommendation (ABR), Merck (MRK) should be added to one's portfolio. Wall Street analysts' overly optimistic recommendations cast doubt on the effectiveness of this highly sought-after metric. So, is the stock worth buying?",
      "url": "https://finnhub.io/api/news?id=523c1e805c44395f4d292b77d7bba21fef8e9317fc950d749126b5591f581a93"
    }
  },
  {
    "ts": null,
    "headline": "TransCelerate BioPharma Showcases Approaches to Advancing Clinical Trial Efficiency and Patient-Centered Design at SCOPE US 2026",
    "summary": "TransCelerate BioPharma (TransCelerate), a nonprofit organization dedicated to improving the health of people around the world by accelerating and simplifying clinical research, will highlight practical, scalable approaches to advancing more efficient, patient-centered clinical trials across the research lifecycle at SCOPE Summit 2026, taking place February 2-5 in Orlando, Florida.",
    "url": "https://finnhub.io/api/news?id=c1a992498f9bac0f92cd284cfde5062818544c1b6f16c27d4322f94e119479f2",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1769607000,
      "headline": "TransCelerate BioPharma Showcases Approaches to Advancing Clinical Trial Efficiency and Patient-Centered Design at SCOPE US 2026",
      "id": 138280643,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "MRK",
      "source": "Yahoo",
      "summary": "TransCelerate BioPharma (TransCelerate), a nonprofit organization dedicated to improving the health of people around the world by accelerating and simplifying clinical research, will highlight practical, scalable approaches to advancing more efficient, patient-centered clinical trials across the research lifecycle at SCOPE Summit 2026, taking place February 2-5 in Orlando, Florida.",
      "url": "https://finnhub.io/api/news?id=c1a992498f9bac0f92cd284cfde5062818544c1b6f16c27d4322f94e119479f2"
    }
  },
  {
    "ts": null,
    "headline": "Global Glioma Market Growth Driven by Therapeutic Innovations and Aging Population",
    "summary": "The Global Glioma Market is focused on managing gliomas, aggressive brain tumors from glial cells. Glioblastoma Multiforme (GBM) is the deadliest type, characterized by rapid growth and invasiveness. Early diagnosis and treatment are crucial for improving patient outcomes. The market is driven by rising glioma cases, advancing cancer therapies, and enhanced diagnostic tools. Challenges include drug resistance, high treatment costs, and complex regulatory issues. Leading companies like Merck & Co",
    "url": "https://finnhub.io/api/news?id=be844d19e718dbc24b1c5f2029e9c25e198fe1cc276b66d02030ff0c0856a114",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1769601840,
      "headline": "Global Glioma Market Growth Driven by Therapeutic Innovations and Aging Population",
      "id": 138280644,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "MRK",
      "source": "Yahoo",
      "summary": "The Global Glioma Market is focused on managing gliomas, aggressive brain tumors from glial cells. Glioblastoma Multiforme (GBM) is the deadliest type, characterized by rapid growth and invasiveness. Early diagnosis and treatment are crucial for improving patient outcomes. The market is driven by rising glioma cases, advancing cancer therapies, and enhanced diagnostic tools. Challenges include drug resistance, high treatment costs, and complex regulatory issues. Leading companies like Merck & Co",
      "url": "https://finnhub.io/api/news?id=be844d19e718dbc24b1c5f2029e9c25e198fe1cc276b66d02030ff0c0856a114"
    }
  },
  {
    "ts": null,
    "headline": "Merck Ends Revolution Medicines Talks As Oncology Plans And Valuation Weighed",
    "summary": "Merck paused acquisition discussions with Revolution Medicines after the two sides could not agree on valuation. The halted talks highlight a shift in Merck's approach to expanding its oncology presence as it reassesses potential deals. This development may influence how investors view both Merck's future transactions and broader pharma M&A activity. Merck, traded as NYSE:MRK, enters this chapter with its shares at $107.92 and a 1-year return of 14.9%. Over 5 years, the stock has returned...",
    "url": "https://finnhub.io/api/news?id=0415c7504f3223765a119bb9f3b0aa75c09b67e762219af8504e4c609390e778",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1769587764,
      "headline": "Merck Ends Revolution Medicines Talks As Oncology Plans And Valuation Weighed",
      "id": 138279103,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "MRK",
      "source": "Yahoo",
      "summary": "Merck paused acquisition discussions with Revolution Medicines after the two sides could not agree on valuation. The halted talks highlight a shift in Merck's approach to expanding its oncology presence as it reassesses potential deals. This development may influence how investors view both Merck's future transactions and broader pharma M&A activity. Merck, traded as NYSE:MRK, enters this chapter with its shares at $107.92 and a 1-year return of 14.9%. Over 5 years, the stock has returned...",
      "url": "https://finnhub.io/api/news?id=0415c7504f3223765a119bb9f3b0aa75c09b67e762219af8504e4c609390e778"
    }
  }
]